Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential ipilimumab versus best supportive care after first-line chemotherapy in advanced gastric or gastro-esophageal junction adenocarcinoma
2011-000853-22Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) comparing Sequential ipilimumab with Best supportive care (2 arms). Primary endpoint: Immune-related progression-free survival. Started May 2012; status: terminated.
02
Drugs
ipilimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2011-000853-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000853-22.